{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:29:48Z","timestamp":1761560988466},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1007\/s11239-005-0355-4","type":"journal-article","created":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T16:09:21Z","timestamp":1119888561000},"page":"47-54","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Platelet Glycoprotein IIb\/IIIa Inhibitor Therapy on In-Hospital Outcomes and Long-Term Survival Following Percutaneous Coronary Rotational Atherectomy"],"prefix":"10.1007","volume":"19","author":[{"given":"Jeffrey S.","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Slater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"355_CR1","first-page":"15","volume":"3","author":"A Khoury","year":"1996","unstructured":"Khoury A, Kern MJ. Coronary physiology of percutaneous rotational atherectomy. Cath Cardiovasc Diag Supplement 1996;3:15\u201322.","journal-title":"Cath Cardiovasc Diag Supplement"},{"key":"355_CR2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.88.3.961","volume":"88","author":"RD Safian","year":"1993","unstructured":"Safian RD, Niazi KA, Strzelecki M, et al. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993;88:961\u2013968.","journal-title":"Circulation"},{"key":"355_CR3","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/0735-1097(91)90505-4","volume":"18","author":"PS Teirstein","year":"1991","unstructured":"Teirstein PS, Warth DC, Haq N, et al. High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol 1991;18:1964\u20131671.","journal-title":"J Am Coll Cardiol"},{"key":"355_CR4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0735-1097(94)90009-4","volume":"24","author":"DC Warth","year":"1994","unstructured":"Warth DC, Leon MB, O\u2019neill W, Zacca N, Polissar NL, Buchbinder M. Rotational atherectomy multicenter registry: Acute results, complications and 6-month angiographic follow-up in 709 Patients. J Am Coll Cardiol 1994;24:641\u2013648.","journal-title":"J Am Coll Cardiol"},{"key":"355_CR5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0002-9149(92)90988-B","volume":"69","author":"ME Bertrand","year":"1992","unstructured":"Bertrand ME, Lablanche JM, Leroy F, et al. Percutaneous transluminal coronary rotary ablation with Rotablator (European experience). Am J Cardiol 1992;69:470\u2013474.","journal-title":"Am J Cardiol"},{"key":"355_CR6","first-page":"402","volume":"39","author":"K Koch","year":"1998","unstructured":"Koch K, Kleinhans E, Klues HG, et al. Quantitative assessment of transient regional ischemia during rotational atherectomy. J Nucl Med 1998;39:402\u2013408","journal-title":"J Nucl Med"},{"key":"355_CR7","first-page":"742","volume":"98","author":"MS Williams","year":"1998","unstructured":"Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abcimixab (c7E3 Fab; ReoPro). Circulation 1998;98:742\u2013748.","journal-title":"latio"},{"key":"355_CR8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","volume":"330","author":"The EPIC Investigators","year":"1994","unstructured":"The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956\u2013961.","journal-title":"N Engl J Med"},{"key":"355_CR9","first-page":"1689","volume":"336","author":"The EPILOG Investigators","year":"1994","unstructured":"The EPILOG Investigators. Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689\u20131696.","journal-title":"N Engl J Med"},{"key":"355_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","volume":"349","author":"The CAPTURE Investigators","year":"1997","unstructured":"The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429\u20131435.","journal-title":"Lancet"},{"key":"355_CR11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","volume":"352","author":"The EPISTENT Investigators","year":"1998","unstructured":"The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. Lancet 1998;352:87\u201392.","journal-title":"Lancet"},{"key":"355_CR12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","volume":"98","author":"SJ Brener","year":"1998","unstructured":"Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734\u2013741.","journal-title":"Circulation"},{"key":"355_CR13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","volume":"349","author":"The IMPACT-II Investigators","year":"1997","unstructured":"The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422\u20131428.","journal-title":"Lancet"},{"key":"355_CR14","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","volume":"356","author":"The ESPRIT Investigators","year":"2000","unstructured":"The ESPRIT Investigators. Novel dosing regimen in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037\u20132044.","journal-title":"Lancet"},{"key":"355_CR15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","volume":"96","author":"The RESTORE Investigators","year":"1997","unstructured":"The RESTORE Investigators. Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445\u20131453.","journal-title":"Circulation"},{"key":"355_CR16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/oxfordjournals.aje.a115470","volume":"131","author":"CA Boyle","year":"1990","unstructured":"Boyle CA, Decoufle P. National sources of vital status information: extent of coverage and possible selectivity in reporting. Am J Epidemiol 1990;131:160\u2013168.","journal-title":"Am J Epidemiol"},{"key":"355_CR17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jamia.1997.0040233","volume":"4","author":"TB Newman","year":"1997","unstructured":"Newman TB, Brown AN. Use of commercial record linkage software and vital statistics to identify patient deaths. J Am Med Inform Assoc 1997;4:233\u2013237.","journal-title":"J Am Med Inform Assoc"},{"key":"355_CR18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1067\/mhj.2001.119382","volume":"142","author":"A Kini","year":"2001","unstructured":"Kini A, Reich, D, Marmur JD, Mitre CA, Sharma SK. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota Reopro randomized trial. Am Heart J 2001;142:965\u2013969.","journal-title":"Am Heart J"},{"key":"355_CR19","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","volume":"103","author":"SR Steinbuhl","year":"2001","unstructured":"Steinbuhl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation 2001;103:2572\u20132578.","journal-title":"Circulation"},{"key":"355_CR20","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.ATV.17.11.3224","volume":"17","author":"A Byrne","year":"1997","unstructured":"Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb\/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 1997;17:3224\u20133229.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"355_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0008-6363(99)00253-9","volume":"45","author":"DJ Schneider","year":"2000","unstructured":"Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res. 2000;45:437\u2013446.","journal-title":"Cardiovasc Res."},{"key":"355_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0049-3848(99)00155-3","volume":"97","author":"U Klinkhardt","year":"2000","unstructured":"Klinkhardt U, Kirchmaier CM, Westrup D, et al. Differential in vitro effects of the platelet glycoprotein IIb\/IIIa inhibitors abciximab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb Res. 2000;97:201\u2013207.","journal-title":"Thromb Res"},{"key":"355_CR23","doi-asserted-by":"crossref","first-page":"16923","DOI":"10.1074\/jbc.274.24.16923","volume":"274","author":"CS Cierniewski","year":"1999","unstructured":"Cierniewski CS, Byzova T, Papierak M, et al. Peptide ligands can bind to distinct sites in integrin \u03b1IIb\u03b23 and elicit different functional responses. J Biol Chem. 1999;274:16923\u201316932.","journal-title":"J Biol Chem"},{"key":"355_CR24","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/blood.V92.9.3240","volume":"92","author":"K Peter","year":"1998","unstructured":"Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb\/IIIa (\u03b1IIb\u03b23) inhibitors. Blood 1998;92:3240\u20133249.","journal-title":"Blood"},{"key":"355_CR25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9149(99)00778-X","volume":"85","author":"MB Holmes","year":"2000","unstructured":"Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy. Am J Cardiol 2000;85:491\u2013493.","journal-title":"Am J Cardiol"},{"key":"355_CR26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0735-1097(98)00659-7","volume":"33","author":"K Koch","year":"1999","unstructured":"Koch K, vom Dahl J, Kleinhans E, et al. Influence of a platelet GPIIb\/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 1999;33:998\u20131004.","journal-title":"J Am Coll Cardiol"},{"key":"355_CR27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/01.CIR.89.2.882","volume":"89","author":"SG Ellis","year":"1994","unstructured":"Ellis SG, Popama JJ, Buchbinder M, et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 1994;89:882\u2013892.","journal-title":"Circulation"},{"key":"355_CR28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/(SICI)1522-726X(199903)46:3<305::AID-CCD9>3.0.CO;2-U","volume":"46","author":"A Kini","year":"1999","unstructured":"Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational Atherectomy: Improved procedural outcome with evolution of technique and equipment. Single center results of first 1,000 patients. Cath Cardiovasc Intervent 1999;46:305\u2013311.","journal-title":"Cath Cardiovasc Intervent"},{"key":"355_CR29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0735-1097(01)01290-6","volume":"37","author":"KA Anderson","year":"2001","unstructured":"Anderson KA, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059\u20132065.","journal-title":"J Am Coll Cardiol"},{"key":"355_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/01.CIR.104.2.163","volume":"104","author":"AM Lincoff","year":"2002","unstructured":"Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2002;104:163\u2013167.","journal-title":"Circulation"},{"key":"355_CR31","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJM200006223422511","volume":"342","author":"SJ Pocock","year":"2000","unstructured":"Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? (editorial). N Engl J Med 2000;342:1907\u20131909.","journal-title":"N Engl J Med"},{"key":"355_CR32","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","volume":"342","author":"J Concato","year":"2000","unstructured":"Concato J, Shah N, Horowitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887\u20131892.","journal-title":"N Engl J Med"},{"key":"355_CR33","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","volume":"342","author":"K Benson","year":"2000","unstructured":"Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878\u20131886.","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-005-0355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-005-0355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-005-0355-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T23:12:20Z","timestamp":1586301140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-005-0355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1007\/s11239-005-0355-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}